Rash in an Immunocompromised Patient
Copyright policy )Rash in an Immunocompromised Patient
A 48-YEAR-OLD MAN WITH LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) undergoes induction chemotherapy with daily all-trans retinoic acid (tretinoin), cytarabine (days 1-7), and daunorubicin (days 1-3). His clinical course is complicated by low-grade fever and a rash on day 15. The rash starts as tender purple papules on the extensor surface of his upper extremities (FIGURE, A) and quickly disseminates to his ears (Figure, B) and shoulders . His vital signs remain stable without hypoxia. Blood culture results are negative, and imaging does not show pulmonary or pericardial effusions. Tretinoin is held on day 21 due to worsening of skin lesions. Subsequently, the rash appears on his lower extremities as well. What Would You Do Next?
- Henry Ford Hospital United States
- Henry Ford Health System United States
Diagnosis, Differential, Male, Immunocompromised Host, Leukemia, Promyelocytic, Acute, Biopsy, Humans, Exanthema, Middle Aged, Sweet Syndrome, Skin
Diagnosis, Differential, Male, Immunocompromised Host, Leukemia, Promyelocytic, Acute, Biopsy, Humans, Exanthema, Middle Aged, Sweet Syndrome, Skin
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).3 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!